Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response-Reference-Cited by-同舟云学术

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

Published:2007-11-01 Issue:1 Volume:47 Page:35-42
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Dalgard Olav,Bjøro Kristian,Ring-Larsen Helmer,Bjornsson Einar,Holberg-Petersen Mona,Skovlund Eva,Reichard Olle,Myrvang Bjørn,Sundelöf Bo,Ritland Ståle,Hellum Kjell,Frydén Aril,Florholmen Jon,Verbaan Hans

Publisher

Wiley

Subject

Hepatology

Reference15 articles.

1. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

2. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

3. Rate and predictors of treatment prescription for hepatitis C;Butt;Gut,2006

4. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose;Hadziyannis;Ann Intern Med,2004

5. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3;Zeuzem;J Hepatol,2004

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing hepatitis C virus distribution among vulnerable populations in London using whole genome sequencing: results from the TB-REACH study;Wellcome Open Research;2021-09-13

2. Genotype 3-hepatitis C virus’ last line of defense;World Journal of Gastroenterology;2021-03-21

3. Global virus outbreaks: Interferons as 1st responders;Seminars in Immunology;2019-06

4. The Evolution of Clinical Trials for Hepatitis C;Topics in Medicinal Chemistry;2019

5. RAPID VIROLOGICAL RESPONSE (RVR) AND END TREATMENT RESPONSE (ETR) IN HEPATITIS C GENOTYPE 3 INFECTED PATIENTS BEING GIVEN SOFOSBUVIR AND RIBAVIRIN COMBINATION (DUAL) THERAPY;INDO AM J PHARM SCI;2018